UnknownPhase 1

A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment

200 participantsStarted 2017-01

Plain-language summary

This study intends to carry out a prospective, randomized, double blind and controlled study to compare the influence of Atosiban and placebo on uterine contraction frequency, endometrial blood flow perfusion, oxytocin and serum concentration of PGF2α, embryo implantation rate and clinical pregnancy rate on the RIF population after fresh embryo transfer, so as to further clarify the curative effect of Atosiban in the treatment of RIF and provide evidence-based basis for Atosiban for application in RIF population.

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 3 or more than 3 embryo implantation failure histories previously (or the number of high-quality embryos transplanted is \>4);
✓. Age \<40 years；
✓. Ultrasound or HSG showed normal uterine cavity, endometrium on transplantation day is ≥ 8mm;
✓. There's at least one good quality embryo on transplantation day.

Exclusion criteria

✕. Patients using donor sperm or donor eggs;
✕. Patients have obvious uterine cavity abnormalities;
✕. There was a clear hydrosalpinx;
✕. Natural cycles or IVM patients;
✕. Patients who cancel the due to the transfer due to various reasons, such as the failure of fertilization, or ovarian transitional stimulus syndrome (OHSS);
✕. Abnormal karyotype;
✕. Blastocyst transplantation patients.

What they're measuring

Clinical pregnancy rate

Timeframe: 4 weeks after embryo transfer

Trial details

NCT IDNCT02893722

SponsorShanghai First Maternity and Infant Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-01

Contact for this trial

Zhi Qin Chen, master

86-21-54035206 ptchen1@hotmail.com

View on ClinicalTrials.gov More Repeated Implantation Failure trials